Dergiler / Solunum / 2015 / Cilt: 17 - Sayı: 3

The Effects of Budesonid that Added to Tiotropium Therapy on Health Related Quality of Life, Exercise Capacity and Pulmonary Functions in COPD Patients

Dergi
Solunum
Sayfa
142–148
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

But this combination is not more effective in improving lung functions

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:The aim of this study was to evaluate the effects of adding inhaled budesonide to the tiotropium treatment on the pulmonary function tests, health-related quality of life and exercise capacity of patients with chronic obstructive pulmonary disease (COPD).
📊
Temel Bulgular & Veri:The patients in the first group was treated with 1x1 18 mcg of Tiotropium and the patients in the second group was treated with the combination of tiotropium (18 mcg 1x1) and budesonide (400 mcg 2x1) for three months.
💡
Sonuç & Katkı:But this combination is not more effective in improving lung functions
🔬Tür:Uygulamalı Anket & Alan Araştırması
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Abstract

The aim of this study was to evaluate the effects of adding inhaled budesonide to the tiotropium treatment on the pulmonary function tests, health-related quality of life and exercise capacity of patients with chronic obstructive pulmonary disease (COPD). Methods: Forty study subjects with COPD were randomized to two groups. The patients in the first group was treated with 1x1 18 mcg of Tiotropium and the patients in the second group was treated with the combination of tiotropium (18 mcg 1x1) and budesonide (400 mcg 2x1) for three months. Pulmonary function tests, six minute walk test, body mass index and Saint George Respiratory Questionnaire (SGRQ) scores were recorded both at the beginning and 3 months later and the results at the begining and third month were compared with each other. There were no statistically significant difference in all basline parameters between the two groups.Results: At the end of the study, no statistically significant differences were obtained between two groups in terms of pulmonary function tests (p>0.05). Significant improvements were observed on the parameters of walking distance (p=0.023) and SGRQ scores (symptom score: p<0.001, activity score: p=0.001, impact score: p=0.003 and total score: p<0.001) in Group 2 when compared with Group 1. Conclusion: These results show that, in patients with COPD, tiotropium/budesonide combination is more effective than alone tiotropium inhalation in quality of life and exercise performance. But this combination is not more effective in improving lung functions

🔖

Bu Makaleye Atıf Yap

ARSLAN, B., TURGUT, T. (2015). The Effects of Budesonid that Added to Tiotropium Therapy on Health Related Quality of Life, Exercise Capacity and Pulmonary Functions in COPD Patients. Solunum, Cilt: 17 - Sayı: 3, 142–148. https://ajindex.com/articles/314284

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (2)

  1. Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease, Revised 2011. www.goldcopd.org. Pauwels RA, Buist AS, Calverley PM, Jenkins CR, Hurd SS, GOLD Scientific Commitee. Global strategy for the diagnosis, management, and preventi- on of chronic obstructive pulmonary disease. NHLBI/WHO global initiati- ve for chronic obstructive lung disease (GOLD) workshop summary. Am J Respir Crit Care Med 2001; 163: 1256-76. [CrossRef] Donohue JF, van Noord JA, Bateman ED, Langley SJ, Lee A, Witek TJ Jr, et al. A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol. Chest 2002; 122: 47-55. [CrossRef] Vincken W, van Noord JA, Greefhorst AP, Bantje TA, Kesten S, Korducki L, et al. Improved health outcomes in patients with COPD during 1 yr's treat- ment with tiotropium. Eur Respir J 2002; 19: 209-16. [CrossRef] Casaburi R, Mahler DA, Jones PW, Wanner A, San PG, ZuWallack RL, et al. A long-term evaluation of once-daily inhaled tiotropium in chronic obstruc- tive pulmonary disease. Eur Respir J 2002; 19: 217-24. [CrossRef] van Noord JA, Bantje TA, Eland ME, Korducki L, Cornelissen PJ. A randomi- sed controlled comparison of tiotropium and ipratropiumin the treatment of chronic obstructive pulmonary disease. The Dutch Tiotropium Study Group. Thorax 2000; 55: 289-94. [CrossRef] Ferrer M, Alonso J, Morera J, Marrades RM, Khalaf A, Aguar MC, et al. Chro- nic obstructive pulmonary disease stage and health-related quality of life. The quality of life of chronic obstructive pulmonary disease study group. Ann Intern Med 1997; 127: 1072-9. [CrossRef] Calverley PMA, Pearson MG. Clinical and laboratuary assesment. Calverley PMA, Mac nee W, Pride NB, Rennard SI (Eds.). Chronic obstructive pulmo- nary disease 2nd.Ed. London, Arnold, 2003: 282-309.
  2. Sterk PJ, Fabbri LM, Quanjer PH, Cockcroft DW, O'Byrne PM, Anderson SD, et al. Airway responsiveness. Standardized challenge testing with pharma- cological, physical and sensitizing stimuli in adults. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. Eur Res- pir J 1993; 16: 53-83. [CrossRef] Quanjer PH, Tammeling GJ, Cotes JE, Pedersen OF, Peslin R, Yernault JC. Lung volumes and forced ventilatory flows. Eur Respir J 1993; 6 (Suppl 16): 5-40. [CrossRef] American Thoracic Society/European Respiratory Society.